Skip to main content

PRA Health Sciences 宣佈委任新董事

Written by Customer Service on . Posted in Public Companies.

北卡羅萊納州羅利, Sept. 17, 2020 (GLOBE NEWSWIRE) — PRA Health Sciences, Inc. (NASDAQ:PRAH) 今天宣佈委任 Glenn Stettin 為公司董事會成員，並於 2020 年 9 月 14 日生效。
PRA health Sciences 董事會主席兼行政總裁 Colin Shannon 說：「我們很高興看到 Glen 加入我們的董事會。Stettin 醫生作為一名醫生及行政人員涉獵廣泛的醫療保健領域，在創新、數據、分析、技術及綜合健康解決方案方面擁有豐富經驗，將為董事會提供寶貴的見解，協助我們繼續重新發明臨床研究，讓患者更容易參與。」Stettin 醫生任職於 Cigna Corporation 旗下的 Express Scripts & Cigna Services，擔任高級副總裁兼創新總裁，負責研發、患者及醫生體驗、產品開發及管理，專注於新的臨床解決方案及數據、分析及平台即服務。此前，Stettin 醫生在 Express Scripts 擔任高級副總裁兼創新總裁，該公司於 2018 年被 Cigna Corporation 收購。Express Scripts 與 Medco Health Solutions, Inc. 於 2012 年 4 月合併，Stettin 醫生亦是在當時加入 Express Scripts。在為 Medco 效力的 17 年期間，他在臨床、營運、技術及產品組織中擔任領導職務。Stettin 醫生獲得理海大學和賓夕法尼亞醫學院的學士及醫學學位。他在加州大學三藩市分校完成內科醫生駐院課程，還擔任 Moffitt-Long Hospital 的首席駐院醫生及心臟科專家，也是加州大學三藩市分校及斯坦福大學 Robert Wood Johnson Foundation 臨床學者。關於 PRA Health Sciences 公司PRA Health Sciences 是按收入計算的全球領先環球合約研究組織之一，為生物技術和製藥業提供承包臨床開發和數據解決方案服務。PRA 的全球臨床開發平台包括位於北美、歐洲、亞洲、拉丁美洲、南非、澳洲和中東等 75 多個辦事處，在全球各地擁有 17,500 多名員工。自 2000 年以來，PRA 已在世界各地參與約 4,000 項臨床試驗。此外 PRA 還參與了不少關鍵或支持性試驗，促成美國食品及藥物管理局或國際監管機構批准超過 95 種產品。要了解有關 PRA 的更多資訊，請瀏覽 www.prahs.com。投資者查詢：InvestorRelations@prahs.com傳媒查詢：Laurie Hurst，傳訊及公共關係總監
hurstlaurie@prahs.com | +1 (919) 786-8435

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.